Data from MDNA55 Clinical Program and IL-2
Superkine Program
TORONTO and HOUSTON, May 4,
2020 /CNW/ - Medicenna Therapeutics Corp.
("Medicenna" or "the Company") (TSX: MDNA, OTCQB:
MDNAF), a clinical stage immuno-oncology company, today announced
that it will be presenting two abstracts at the American Society of
Clinical Oncology ("ASCO") Virtual Scientific Program to be
held from May 29 to May 31, 2020.
The first abstract has been selected for a poster discussion and
will provide new data on tumor response as well as survival
outcomes compared to a matched Synthetic Control Arm
("SCA"). Details of the poster discussion presentation are
below:
|
Presenter:
|
Dr. John Sampson, MD,
PhD, MHSc, MBA, Robert H. and Gloria Wilkins
Distinguished Professor and Chair of Neurosurgery, Duke University
School of
Medicine
|
|
Title:
|
"MDNA55 survival in
recurrent glioblastoma ("rGBM") patients expressing the
interleukin-4 receptor ("IL4R") as compared to a matched
synthetic control"
|
|
Abstract
#:
|
2513
|
|
Session
Title:
|
CNS Tumors
|
|
Discussant:
|
Dr. Ian Parney, MD,
PhD
|
The second abstract will present pre-clinical data including
non-human primate data for MDNA11, one of Medicenna's IL2 Superkine
candidates. Details of the poster presentation are below:
|
Presenter:
|
Dr. Moutih Rafei,
PhD, Associate Professor, Department of Pharmacology and
Physiology, Université de Montreal
|
|
Title:
|
"In vitro and
in vivo characteristics of MDNA11: A long-acting
'Beta-only'
IL-2 Superkine in syngeneic mice tumor models and non-human
primates"
|
|
Abstract
#:
|
3036
|
|
Session
Title:
|
Developmental
Therapeutics Immunotherapy
|
Presentations and posters will be available for on-demand
viewing online at https://meetings.asco.org/am/virtual-program
beginning on May 29, 2020 at
8:00 a.m. ET.
About Medicenna Therapeutics Corp.
Medicenna is a
clinical stage immunotherapy company focused on the development of
novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines
and first in class Empowered Cytokines™ (ECs) for the treatment of
a broad range of cancers. Medicenna's lead IL4-EC, MDNA55, has
completed a Phase 2b clinical trial for rGBM, the most
common and uniformly fatal form of brain cancer. MDNA55 has been
studied in five clinical trials involving 132 patients, including
112 adults with rGBM. MDNA55 has demonstrated compelling efficacy
and has obtained Fast-Track and Orphan Drug status from the FDA and
FDA/EMA respectively. Medicenna's long-acting IL2 Superkine assets,
MDNA19 and MDNA11, are best-in-class next-generation IL-2's in
development with superior CD122 binding without CD25 affinity and
therefore preferentially stimulating cancer killing effector T
cells and NK cells when compared to competing IL-2 programs. It is
anticipated that MDNA19 or MDNA11 will be ready for the clinic in
2021. For more information, please
visit www.medicenna.com.
This news release contains forward-looking statements
relating to the future operations of the Company and other
statements that are not historical facts. Forward-looking
statements are often identified by terms such as "will", "may",
"should", "anticipate", "expects", "believes" and similar
expressions. All statements other than statements of historical
fact, included in this release, including, without limitation,
statements related to Medicenna's long-acting IL2 Superkine assets
being best-in-class and ready for the clinic in 2021 and the future
plans and objectives of the Company, are forward-looking statements
that involve risks and uncertainties. There can be no assurance
that such statements will prove to be accurate and actual results
and future events could differ materially from those anticipated in
such statements. Important factors that could cause actual results
to differ materially from the Company's expectations include the
risks detailed in the annual information form of the Company dated
June 24, 2019 and in other filings
made by the Company with the applicable securities regulators from
time to time.
The reader is cautioned that assumptions used in the
preparation of any forward-looking information may prove to be
incorrect and that study results could change over time
as the study is continuing to follow up all patients and new data
are continually being received which could materially change study
results. Events or circumstances may cause actual results to
differ materially from those predicted, as a result of numerous
known and unknown risks, uncertainties, and other factors, many of
which are beyond the control of the Company. The reader is
cautioned not to place undue reliance on any forward-looking
information. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement. The
forward-looking statements contained in this news release are made
as of the date of this news release and the Company will update or
revise publicly any of the included forward-looking statements only
as expressly required by Canadian securities law.
View original
content:http://www.prnewswire.com/news-releases/medicenna-announces-upcoming-presentations-at-the-asco-annual-meeting-301051491.html
SOURCE Medicenna Therapeutics Corp.
